Sign Out
Each mL contains 20 mg of tremelimumab.
Each vial of 15 mL contains 300 mg of tremelimumab.
IMJUDO is a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4)- immunoglobulin G2 (IgG2a) monoclonal antibody produced in murine myeloma cells by recombinant DNA technology.
Concentrate for solution for infusion; 20 mg/mL in a single-dose vial for intravenous administration.
Sterile, preservative-free, clear to slightly opalescent, colourless to slightly yellow solution, free from or practically free from visible particles.
Excipients/Inactive Ingredients: L-histidine, L-histidine hydrochloride monohydrate, α,α-Trehalose dihydrate, Disodium edetate dihydrate, Polysorbate 80, Water for Injection.
